Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials. Summarizes the sensitizing role of some tyrosine kinase inhibitors in existing research Brings recent findings in several cancer types, both experimental and clinically, with a particular emphases on underlying biochemical, genetic, and molecular mechanisms Provides an updated and comprehensive knowledge regarding the field of combinational cancer treatment

Produk Detail:

  • Author : Anonim
  • Publisher : Academic Press
  • Pages : 292 pages
  • ISBN : 0128127384
  • Rating : 5/5 from 1 reviews
CLICK HERE TO GET THIS BOOKProtein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
  • Author : Anonim
  • Publisher : Academic Press
  • Release : 21 November 2018
GET THIS BOOKProtein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic,

Paclitaxel

Paclitaxel
  • Author : Mallappa Kumara Swamy,T. Pullaiah,Zhe-Sheng Chen
  • Publisher : Academic Press
  • Release : 01 January 2022
GET THIS BOOKPaclitaxel

Paclitaxel: Sources, Chemistry, Anticancer Actions, and Current Biotechnology provides a comprehensive survey of Paclitaxel and its derivatives chemistry, biosynthesis, and anticancer activities. In addition, biotechnological methods, including cell cultures, the use of bioreactors and metabolic engineering strategies to improve Paclitaxel production are also discussed. The book discusses topics such as mechanisms of action against cancer, novel forms of Paclitaxel for an effective cancer treatment, strategies for enhancing its bioavailability, application of nanocarriers for its delivery and chemotherapy of cancer. In

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies
  • Author : Ramasamy Paulmurugan,Tarik F. Massoud
  • Publisher : Academic Press
  • Release : 25 June 2021
GET THIS BOOKGlioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists,

Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy

Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy
  • Author : Anonim
  • Publisher : Academic Press
  • Release : 07 November 2019
GET THIS BOOKDrug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy

Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy, Volume Seven, describes the fundamental aspects of efflux pumps of the ATP-binding cassette superfamily in cancer resistance pathways, along with strategies to target and improve chemotherapy efficacy. Pumps of the ATP-binding cassette superfamily (ABCs) regulate the access of drugs to the intracellular space. In this context, the overexpression of ABCs is a well-known mechanism of multidrug resistance in cancer and is associated

pH-Interfering Agents as Chemosensitizers in Cancer Therapy

pH-Interfering Agents as Chemosensitizers in Cancer Therapy
  • Author : Claudiu Supuran,Simone Carradori
  • Publisher : Academic Press
  • Release : 15 September 2020
GET THIS BOOKpH-Interfering Agents as Chemosensitizers in Cancer Therapy

pH Interfering Agents as Chemosensitizers In Cancer Therapy, Volume Thirteen, provides a detailed overview of the chemosensitizers for the treatment of cancer spanning from biochemical and structural features to pharmacology and drug-design, including technological applications. The book is structured with innovative outlines and a distinction between experimental and clinical results. The continuous discovery and assessment of the role played by old/new synthetic drugs, natural compounds and technological applications has led to the urgent need of classification in terms of

Prognostic and Therapeutic Applications of Rkip in Cancer

Prognostic and Therapeutic Applications of Rkip in Cancer
  • Author : Benjamin Bonavida,Stavroula Baritaki
  • Publisher : Academic Press
  • Release : 02 March 2020
GET THIS BOOKPrognostic and Therapeutic Applications of Rkip in Cancer

Prognostic and Therapeutic Applications of RKIP in Cancer provides updated reviews on the chemistry, signaling, pre-clinical and clinical activities, and role of RKIP expression levels for diagnostics, prognosis and potential interventions. The development of novel compounds and conjugates that selectively induce RKIP expression in cancer open a novel era of new therapeutics and their potential in the treatment of highly resistant cancers and metastases. Edited and written by internationally renowned experts in the field of novel therapeutics for cancer, this

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance
  • Author : Andrew Freywald,Franco Vizeacoumar
  • Publisher : Academic Press
  • Release : 04 December 2020
GET THIS BOOKBiological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it

Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance
  • Author : Goli Samimi,Christina Annunziata
  • Publisher : Academic Press
  • Release : 06 November 2020
GET THIS BOOKOvercoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment.

Therapeutic Strategies to Overcome ALK Resistance in Cancer

Therapeutic Strategies to Overcome ALK Resistance in Cancer
  • Author : Luc Friboulet
  • Publisher : Academic Press
  • Release : 18 January 2021
GET THIS BOOKTherapeutic Strategies to Overcome ALK Resistance in Cancer

Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance

Protein Kinase Inhibitors in Research and Medicine

Protein Kinase Inhibitors in Research and Medicine
  • Author : Anonim
  • Publisher : Academic Press
  • Release : 01 July 2013
GET THIS BOOKProtein Kinase Inhibitors in Research and Medicine

This new volume of Methods in Enzymology continues the legacy of this premier serial with quality chapters authored by leaders in the field. This volume covers protein kinase inhibitors in research and medicine, and includes chapters on such topics as fragment-based screening, broad kinome profiling of kinase inhibitors, and designing drug-resistant kinase alleles. Continues the legacy of this premier serial with quality chapters authored by leaders in the field Covers research methods in biomineralization science Contains sections focusing on protein

Overcoming Drug Resistance in Gynecologic Cancers

Overcoming Drug Resistance in Gynecologic Cancers
  • Author : Anonim
  • Publisher : Academic Press
  • Release : 20 August 2021
GET THIS BOOKOvercoming Drug Resistance in Gynecologic Cancers

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and

New Targeting in The Reversal of Resistant Glioblastomas

New Targeting in The Reversal of Resistant Glioblastomas
  • Author : Ali Syed Arbab
  • Publisher : Academic Press
  • Release : 18 March 2021
GET THIS BOOKNew Targeting in The Reversal of Resistant Glioblastomas

New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource

Epigenetic Regulation in Overcoming Chemoresistance

Epigenetic Regulation in Overcoming Chemoresistance
  • Author : Chunfu Wu,Lihui Wang
  • Publisher : Academic Press
  • Release : 26 June 2021
GET THIS BOOKEpigenetic Regulation in Overcoming Chemoresistance

Epigenetic Regulation in Overcoming Chemoresistance, Volume 19, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally,

Resistance to Tyrosine Kinase Inhibitors

Resistance to Tyrosine Kinase Inhibitors
  • Author : Daniele Focosi
  • Publisher : Springer
  • Release : 07 November 2016
GET THIS BOOKResistance to Tyrosine Kinase Inhibitors

The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.

Early Detection and Treatment of Head & Neck Cancers

Early Detection and Treatment of Head & Neck Cancers
  • Author : Rami El Assal,Dyani Gaudilliere,Stephen Thaddeus Connelly
  • Publisher : Springer Nature
  • Release : 07 May 2021
GET THIS BOOKEarly Detection and Treatment of Head & Neck Cancers

Head and neck cancer (HNC) is a heterogeneous group of cancers that, if combined, represent one of the most common cancer types. Patients with HNC suffer significant morbidity and mortality due to the importance of the structures involved. Over two-thirds of these patients are diagnosed at a late stage, leading to a poor prognosis. Therefore, advancements in early detection and treatment of HNC are crucial. Volume I begins with a general overview, including the industry landscape, of HNC detection, diagnosis,